Drugs / CI-581b
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT05690503 | Mar 2023 → Jun 2025 overdue | cognitive disorder, depressive disorder, long COVID-19 | New York State Psychiatric Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02596022 | Jun 2013 → Jun 2015 | cocaine dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT04084860 Comparator | Nov 2019 → Aug 2024 overdue | alcohol-related disorders | New York State Psychiatric Institute | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02539511 Comparator | Jul 2015 → Sep 2017 | alcohol dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 3 | NCT03344419 Comparator | Oct 2017 → Dec 2024 | substance-related disorder | New York State Psychiatric Institute | Suspended | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CI-581b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05690503 ↗ |
| Route | Intravenous | “Medication infusion intravenously over 1 hour.” NCT03344419 ↗ |